- Your selection
- Clear all
- Pharmaceuticals x
- Economics & Finance x
4 cases found.
This is a two-party negotiation between a pharmaceutical company and a government agency to decide if a new medication will be put on the reimbursement list. The pharmaceutical company has a valuable new product, the government has semi-monopolistic power over whether (or not) drugs are listed.
- By 
Reference 6033
Published 27 Jan 2014
Topic Economics & Finance
Region Global
Industry Pharmaceuticals
This is a two-party negotiation between a pharmaceutical company and a government agency to decide if a new medication will be put on the reimbursement list. The pharmaceutical company has a valuable new product, the government has semi-monopolistic power over whether (or not) drugs are listed.
This is a two-party negotiation between a pharmaceutical company and a government agency to decide if a new medication will be put on the reimbursement list. The pharmaceutical company has a valuable new product, the government has semi-monopolistic power over whether (or not) drugs are listed.
- By 
Reference 6033
Published 27 Jan 2014
Topic Economics & Finance
Region Global
Industry Pharmaceuticals
This is a two-party negotiation between a pharmaceutical company and a government agency to decide if a new medication will be put on the reimbursement list. The pharmaceutical company has a valuable new product, the government has semi-monopolistic power over whether (or not) drugs are listed.
The Lundbeck case study describes the initial public offering (IPO) that the company made in the summer of 1999.
- By 
Reference 4927
Published 01 Dec 2000
Topic Economics & Finance
Region Europe
Industry Pharmaceuticals
The Lundbeck case study describes the initial public offering (IPO) that the company made in the summer of 1999.
Business has traditionally enjoyed a pre-eminent position in the Swiss political economy. This case looks at political conflicts over chemicals and biotechnology regulation and Swiss entry into the European Economic Area, showing how the growing environmentalist movements have challenged this position and that important changes in the Swiss political economy may be imminent.
- By 
Reference 4222
Published 01 Jan 1993
Topic Economics & Finance
Region Europe
Industry Pharmaceuticals, Biotechnology, Chemicals
Business has traditionally enjoyed a pre-eminent position in the Swiss political economy. This case looks at political conflicts over chemicals and biotechnology regulation and Swiss entry into the European Economic Area, showing how the growing environmentalist movements have challenged this position and that important changes in the Swiss political economy may be imminent.